Micardis, Telmisartan News

Promega luciferase assays were subsequently used for the detection of PPARgamma activation.

Main Category: Heart Disease Also Included In: Stroke Article Date: 28 Nov 2009 - 0:00 PST printer friendly view / write opinions rate article MICARDIS has received Health Canada approval to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in patients 55 years or older at high risk of developing major cardiovascular events who ...

Boehringer Ingelheim announced today that the European Commission has approved MICARDISA for the reduction of cardiovascular morbidity in patients with: I. manifest atherothrombotic cardiovascular disease or, II.

High risk of cardiovascular events includes evidence of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or diabetes mellitus with evidence of end-organ damage.

Ku et al1 cite the findings of the Renal Outcomes With Telmisartan, Ramipril, or Both, in People at High Vascular Risk trial2 in arguing against dual renin-angiotensin system inhibition in chronic kidney disease.

From the Stroke Trials Unit , University of Nottingham, UK; Department of Biostatistics, Bioinformatics, and Epidemiology , Medical University of South Carolina, Columbia, SC; Biostatistics , Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn; Population Health Research Institute , McMaster University, Hamilton, Canada; Division of Neurology , ...

Stroke Boehringer Ingelheim announced that the US Food and Drug Administration has approved a new indication for MICARDIS for the reduction of the risk of myocardial infarction , stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.

INGELHEIM,A Germany The Food and Drug Administration has approved an additional use for Boehringer Ingelheim's Micardis , a hypertension drug.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration approved the supplemental New Drug Application for its angiotensin II receptor blocker Micardis A Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at ...

October 16, 2009 - The United States Food and Drug Administration has approved Twynsta an angiotensin II receptor blocker and a dihydropyridine calcium channel blocker combination product indicated for the treatment of hypertension alone or with other antihypertensive agents.

Hypertension. 2009 Published online before print October 12, 2009, doi: 10.1161/HYPERTENSIONAHA.109.138750 Submitted on July 2, 2009 Revised on July 13, 2009 Telmisartan-Induced Inhibition of Vascular Cell Proliferation Beyond Angiotensin Receptor Blockade and Peroxisome Proliferator-Activated Receptor- Activation Koichi Yamamoto*; Mitsuru Ohishi; ...

Paolo Verdecchia, MD ; Peter Sleight, MD ; Giuseppe Mancia, MD ; Robert Fagard, MD, PhD ; Bruno Trimarco, MD ; Roland E. Schmieder, MD ; Jae-Hyung Kim, MD ; Garry Jennings, MBBS, PhD ; Petr Jansky, MD ; Jyh-Hong Chen, MD ; Lisheng Liu, MD ; Peggy Gao, MSc ; Jeffrey Probstfield, MD ; Koon Teo, MD ; Salim Yusuf, MD, DPhil, FRCPC , for the ...

Philip M. W. Bath MD, FRCP*; Rene H. Martin PhD; Yuko Palesch PhD; Daniel Cotton MS; Salim Yusuf MB, BS, DPhil; Ralph Sacco MD; Hans-Christoph Diener MD, PhD; Danilo Toni MD; Conrado Estol MD, PhD; Robin Roberts MSc; for the PRoFESS Study Group From the Stroke Trials Unit , University of Nottingham, UK; Department of Biostatistics, Bioinformatics, ...

Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension 1Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA 2Medical Department, Boehringer Ingelheim Pharmaceuticals, ...

From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy ; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada ; Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK ; University of Milano-Bicocca, Milano, Italy ; Hypertension Unit, Catholic University of ...

Original Articles Cognitive Deficit in Amyloid-I2-Injected Mice Was Improved by Pretreatment With a Low Dose of Telmisartan Partly Because of Peroxisome Proliferator-Activated Receptor- Activation Kana Tsukuda ; Masaki Mogi ; Jun Iwanami ; Li-Juan Min ; Akiko Sakata ; Fei Jing ; Masaru Iwai ; Masatsugu Horiuchi From the Department of Molecular ...

The American Diabetes Association held its 2009 annual meeting from June 5 to 9 in New Orleans.

We read with interest the article by Davis et al1 about the risk of hospitalization for heart failure in the patients included in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial .

Hypertension. 2009 Published online before print July 27, 2009, doi: 10.1161/HYPERTENSIONAHA.109.136879 Submitted on May 28, 2009 Revised on June 9, 2009 Cognitive Deficit in Amyloid- -Injected Mice Was Improved by Pretreatment With a Low Dose of Telmisartan Partly Because of Peroxisome Proliferator-Activated Receptor- Activation Kana Tsukuda; ...

Seventy-two drug products will be sold 50% cheaper than their present regular prices starting August 15, Health Secretary Francisco Duque said in a press conference on Friday.